NCT00036413View on ClinicalTrials.gov

A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

October 31, 2002

Study Completion Date

October 31, 2002

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

TCH346

Trial Locations (1)

10032

Neurological Institute, New York

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY